Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORFEO: DTG vs DRV/c Neuropsychiatric Effects in HIV
NCT06787976Phase 4Not yet recruiting
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by Instituto Mexicano del Seguro Social. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06787976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787976.